Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses: Rapamycin efficacy is blood level related

Transplantation

Volumn 56, Issue 6, 1993, Pages 1293-1298

  Yakimets, Walter J ^a   Lakey, Jonathan R T ^a   Yatscoff, Randall W ^b   Katyal, Deepak ^a   Ao, Ziliang ^a   Finegood, Diane T ^a   Rajotte, Ray V ^a   Kneteman, Norman M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MIXTURE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

ANIMAL; BLOOD GLUCOSE; CYCLOSPORINE; DOGS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; POLYENES; SIROLIMUS; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0027717739     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199312000-00001     Document Type: Article

References (36)

1. Kahan BD. The impact of cyclosporine on the practice of renal transplantation. Transplant Proc 1989; 21; 63.
2. Whiting PH, Thomson AW. Pathological effects of cyclosporin A in experimental models. In: Thomson AW, ed. Cyclosporin: mode of action and clinical applications. London: Kluwer Academic, 1989: 302.
3. Collier St J. Immunosuppressive drugs. Curr Opin Immunol 1990; 2: 854.
4. Sehgal SN, Baker H, Vezina C. Rapamycin (Ay-22,989), a new antifungal antibiotic: II. Fermentation, isolation, and characterization. J Antibiot (Tokyo) 1975; 28: 727.
5. Strepkowski SM, Chen H, Daloze P, Kahan BD. Rapamycin, a potent immunosuppressive drug for heart, kidney, and small bowel transplantation. Transplant Proc 1991; 51: 22.
6. Kimball PM, Kerman RH, Kahan BD. Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 1991; 51: 486.
7. Alejandro R, Cutfield R, Shienvold F, Latif Z, Mintz D. Successful long-term survival of pancreatic islet allografts in spontaneous or pancreatectomy-induced diabetes in dogs: cyclosporine induced immune unresponsiveness. Diabetes 1985; 34:825.
8. Kneteman NM, Alderson D, Scharp DW. Long-term normogly-cemia in pancreatectomized dogs following pancreatic islet allotransplantation and cyclosporine immunosuppression. Transplantation 1987; 44: 595.
9. Cattral MS, Wamock GL, Kneteman NM, Rajotte RV. Transplan tation of purified single-donor canine islet allografts with cyclosporine. Transplantation 1989; 47: 583.
10. Scharp DW, Lacy PE, Santiago JV, et al. Insulin independence after islet transplantation into type 1 diabetic patients. Diabetes 1990; 39: 515.
11. Wamock GL, Kneteman NM, Ryan E, et al. Normoglycaemia after transplantation of freshly isolated and cryopreserved pancreatic islets in type 1 (insulin-dependent) diabetes mellitus. Diabeto-logia 1991; 34: 55.
12. Carroll PB, Ricordi C, Shapiro R, et al. Frequency of kidney rejection in diabetic patients undergoing simultaneous kidney and pancreatic islet cell transplantation. Am Soc Transplant Surg Meet 1992.
13. Andersson A, Borg H, Hallberg, et al. Long-term effects of cyclo sporine A on cultured mouse pancreatic islets. Diabetologia 1984; 41: 66.
14. Rooth PE, Dawidson K, Laferty K, et al. Prevention of detrimental effect of cyclosporin A on vascular ingrowth of transplanted pancreatic islets with Verapamil. Diabetes 1989; 38 (suppl 1): 202.
15. McNaiy WF. Zinc-dithizone reaction of pancreatic ialets. J Histo-chem Cytochem 1954; 2: 185.
16. Wamock GL, Dabbs KD, Evans MG, Cattral MS, Kneteman NM, Rajotte RV. Critical mass of islets that function after implantation in a large mammalian. In: Pfeiffer EF, Reaven GM, eds. Methods in islet transplantation research. New York: Thieme, 1990:156.
17. Wamock GL, Rqjotte RV, Procyshyn AW. Normoglycemia after reflux of islet-containing pancreatic fragments into the splenic vascular bed in dogs. Diabetes 1983; 32: 452.
18. Bergman RN, Beard JC, Chen M. The minimal modeling method: assessment of insulin sensitivity and B-cell function in vivo. In: Clarke WL, Lamer J, Pohl SL, eds. Methods in diabetes research. Clinical methods, Vol 2. New York: Wiley, 1986:15.
19. Moorehouse JA, Grahman GR, Rosen NJ. Relationship between intravenous glucose tolerance and the fasting plasma glucose level in healthy and diabetic subjects. J Clin Endocrinol 1964; 24:145.
20. Morgan CR, Lazarow A. Immunoassay of insulin: two antibody system plasma insulin levels of normal, subdiabetic and diabetic rats. Diabetes 1963; 12:673.
21. Copeland K, Yatscoff R. Use of a monoclonal antibody for the therapeutic monitoring of cyclosporine in plasma and whole blood. Ther Drug Monit 1988; 10:453.
22. Yatscoff RW, Faraci C, Bolingbroke P. Measurement of rapamycin in whole blood using reverse-phase high-performance liquid chromatography. Ther. Drug Monit. 1991; 14:138.
23. Fryer J, Yatscoff RW, Pascoe EA, Thliveris J. Relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model. Transplantation (in press).
24. Kneteman NM, Wamock GL, Evans MG, Nason RW, Rajotte RV. Prolonged fonction of canine pancreatic fragments autotrans-planted to the spleen by venous reflux. Transplantation 1990; 49: 679.
25. Kimball PM, Kerman RH, Kahan BD. Rapamycin and cyclospor ine produce synergistic but nonidentical mechanisms of immunosuppression. Transplant Proc 1991; 23:1027.
26. Kahan BD, Gibbons S, Tejpal N, Chou TC, Stepkowski S. Syner gistic effect of the rapamycin-cyclosporine combination: median analysis of in vitro immune performances by human T lymphocytes in PHA, CD3, and MLR proliferative and cytotoxicity assays. Transplant Proc 1991; 23:1090.
27. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou TC. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal peripheral blood lymphocytes in vitro. Transplantation 1991; 51: 232.
28. Metcalf SM, Richards FM. Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. Transplantation 1990; 144: 251.
29. June CH. Signal transduction in T cells. Curr. Opin. Immunol. 1991; 3: 287.
30. Kuo CJ, Chung J, Fioventino DF, et al. Rapamycin selectively inhibits interleukin-2 activation of p70S6 kinase. Nature 1992; 358(6381): 70.
31. Collier St. J, Caine R, Thiru S, et al. Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc 1990; 22:1674.
32. Whiting PH, Woo J, Adam BJ, et al. Toxicity of rapamycin-comparative and combination study with cyclosporine at immu-notherapeutic dosage in the rat. Transplantation 1991; 52: 203.
33. Fabian MC, Lakey JRT, Kneteman NM. Rapamycin prolongs murine islet allograft survival. Transplantation (in press).
34. Honcharik N, Fryer J, Yatscoff RW. Pharmacokinetics of rapa mycin: single dose studies in the rabbit. Ther Drug Monit 1992; 14: 475.
35. Morris RE. In vivo immunopharmacology of the macrolides FK506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. Transplant Proc 1991; 23: 2722.
36. Morris RE. Immunopharmacology of new xenobiotic immunosup pressive molecules. Semin Nephrol 1992; 13: 304.